论文部分内容阅读
目的:总结单药S-1及S-1联合奥沙利铂(SOX)治疗老年晚期胃癌的疗效及安全性。方法:将2010年1月至2013年12月我院收治的符合研究条件的老年晚期胃癌患者74例根据化疗方法分为S-1组(n=48)和SOX组(n=26),比较两组的疗效及安全性。结果:S-1组的治疗反应率、中位OS期、中位无进展生存(PFS)时间均明显短于SOX组(27.1%vs 42.3%、9.2月vs 15.3月、4.1月vs 7.3月),P均<0.05;S-1组的白细胞降低、中性粒细胞降低、食欲下降、恶心、呕吐、感觉神经病的发生率均明显高于SOX组(23.1%vs 4.2%、26.9%vs 6.3%、26.9%vs 16.7%、23.1%vs 4.2%、15.4%vs 0.0%、15.4%vs 0.0%),P均<0.05。结论 :与S-1方案比较,SOX方案可提高老年晚期胃癌患者OS,且耐受性良好。
Objective: To summarize the efficacy and safety of monotherapy with S-1 and S-1 in combination with oxaliplatin (SOX) in the treatment of elderly patients with advanced gastric cancer. Methods: Seventy-four elderly patients with advanced gastric cancer admitted to our hospital from January 2010 to December 2013 were divided into S-1 group (n = 48) and SOX group (n = 26) according to chemotherapy. Efficacy and safety of the two groups. RESULTS: Response rates, median OS, and median progression-free survival (PFS) were significantly shorter in the S-1 group than in the SOX group (27.1% vs 42.3%, 9.2 vs 15.3, 4.1, vs 7.3 months) (P <0.05). The incidences of leukopenia, neutropenia, loss of appetite, nausea, vomiting and sensory neuropathy in S-1 group were significantly higher than those in SOX group (23.1% vs 4.2%, 26.9% vs 6.3% , 26.9% vs 16.7%, 23.1% vs 4.2%, 15.4% vs 0.0%, 15.4% vs 0.0% respectively), P <0.05. Conclusion: Compared with S-1 regimen, SOX regimen can improve OS of elderly patients with advanced gastric cancer and is well tolerated.